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Abstract
Objective : Delay on diagnosing GTN may increase the GTN 
score from low risk become high risk, as follow. 
Methods : case report
Results : Mrs I, 29 yo, P1A7 came with vaginal bleeding. 
Four months before admission, she had surgery of ectopic 
pregnancy, and the left salphynx and ovary had already 
taken out. No histopathology examination was performed. 
After the surgery, she had vaginal bleeding and underwent 
curettage, but the tissue was not sent for histopathology 
exam. US exam one week after procedure shows mass 
protruding in the uterine, with BhCG 225.000 IU/ml. The 
patient was planned to undergo chemotherapy. While 
waiting for chemotherapy, patient complaints of acute 
abdomen due to hemoperitoneum due to perforation of 
trophoblastic mass. Emergency laparotomy was performed.
Conclusions : Inadequate treatment due to inadequate 
staging is the most common reason for unsuccessful GTN 
treatment, and increase patient morbidity. Histopathology 
result also plays an important role to decide the mode of 
treatment should be given since PSTT and ETT treatment of 
choice is not using chemotherapy.
Keywords : ectopic pregnancy, gestational trophoblastic 
neoplasia, molar gestation, vaginal bleeding pathology.
Abstrak
Tujuan : Penundaan dalam mendiagnosis GTN dapat 
meningkatkan skor GTN dari risiko rendah menjadi risiko 
tinggi, sebagai berikut.
Metode : laporan kasus
Hasil : Ny. I, 29 tahun, P1A7 datang dengan pendarahan 
vagina. 4 bulan sebelum masuk, dia menjalani operasi 
kehamilan ektopik, dan salphynx dan ovarium kiri sudah 
diambil. Tidak ada pemeriksaan histopatologi yang 
dilakukan. Setelah operasi, dia mengalami pendarahan 
vagina dan menjalani kuret, tetapi jaringan itu tidak dikirim 
untuk pemeriksaan histopatologi. Ujian AS 1 minggu 
setelah prosedur menunjukkan massa menonjol di uterus, 
dengan BhCG 225.000 IU / ml. Rencanakan kemoterapi. 
Sambil menunggu kemoterapi, keluhan pasien perut akut 
karena hemoperitoneum karena perforasi massa trofoblas. 
Laparotomi darurat dilakukan.
Kesimpulan : pengobatan yang tidak memadai karena 
pementasan yang tidak memadai adalah alasan yang 
paling umum dari pengobatan GTN tidak berhasil,  dan 
meningkatkan morbiditas pasien. Hasil histopatologi 
juga memainkan peran penting untuk menentukan cara 
pengobatan yang harus diberikan, karena pilihan pengobatan 
PSTT dan ETT tidak menggunakan kemoterapi.
Kata kunci : kehamilan ektopik, kehamilan mola, neoplasia 
trofoblastik gestasional, patologi perdarahan pervaginam.
INTRODUCTION
A delay on diagnosing Gestational Trophoblastic 
Neoplasia (GTN) may cause an increase of 
morbidity to the patient. The important things that 
OBGYN usually forgot are that GTN may develop 
not only from previous molar gestation (50-60%), 
but also from abortions or ectopic pregnancy 
(25-30%) and term or preterm deliveries (10-
25%).1,2This can cause a delay on diagnosing that 
may increase the GTN score from low risk become 
high risk, such as this case, as follow. 
CASE 
Mrs I, 29 yo, P1A7 came with vaginal bleeding. 
Four months before admission, she had surgery 
of ectopic pregnancy, and the left salphynx and 
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ovary had already taken out. No histopathology 
examination was performed. After the surgery, she 
had vaginal bleeding and underwent curettage, 
but the tissue was not sent for histopathology 
exam. She had US exam one week later, there 
is tissue remnant and invaded to the uterine 
wall, given primolut for 15 days, then checked 
for b-hCG, and the result was 225.000 IU/ml. 
The patient was then referred to our hospital. 
Ultrasonographic fi ndings found a solid mass on 
the posterior part, irregular, no clear border, size 
60x10 mm malignant trophoblastic mass. Mass 
on left anterior corpus invaded the left adnexa, 
left ovary sized 100x110 mm. Liver, spleen, and 
both kidneys were normal. Conclusion: malignant 
trophoblastic disease with invasion to left 
adnexa.
Based on the fact that there were several cases 
of GTN found too late, we try to explain about 
GTN "What, When, How to Treat and What to 
do Next ?" What kind of GTN could be managed 
by general obgyn and when to refer the patient 
to Oncology-gynecologist. In this article, only 
treatment with single-agent chemotherapy will 
be discussed deeply.
What is Gestational Trophoblastic Neoplasia 
(GTN)?
Gestational trophoblastic neoplasia (GTN) is the 
term used to describe malignant lesions that 
originate in the chorionic villi and the extravillous 
trophoblast. GTN includes four different 
proliferation, invasion and dissemination, such 
as invasive mole (IM), choriocarcinoma (CCA), 
placental site trophoblastic tumour (PSTT) and 
epithelioid trophoblastic tumour (ETT). The 
overall cure rate with chemotherapy is around 
90%, but for PSTT and ETT are relatively resistant 
for chemotherapy.2 Therefore, the fi rst-line 
treatment in these cases is surgery, particularly 
in no metastatic cases3.PSTT and ETT, however, 
develop after term deliveries or non-molar 
abortions in 95% of the cases4.
When we have to think about GTN?
Most of GTN develops from postmolar gestation 
(50-60%) while GTN could also develop from 
previous abortion, ectopic pregnancy and term or 
preterm deliveries.1-3Following a molar pregnancy, 
the risk of a further hydatidiform mole increases 
around 1%.5,6 After two molar gestations, the risk 
of a third mole is 15%–20% and is not decreased 
by changing partners.7 Most of  PSTT and ETT 
(95%) usually develop after term delivery or non-
molar abortion2. That is why the pathology result 
of the tissue that had been evacuated previously 
plays a vital role in diagnosing GTN.
The components needed to diagnose 
postmolar GTN, based on FIGO 2002 include 
at least 1 of the following; hCG plateau for 4 
consecutive values over 3 weeks; hCG rise of 
≥10% for 3 values over 2 weeks; hCG persistence 
6 months after molar evacuation;  histopathologic 
diagnosis of choriocarcinoma; or presence of 
metastatic disease. While PSTT and ETT are 
classifi ed separately.1-3 hCG value measured after 
mole evacuation use as a reference value. A rise, 
While waiting for chemotherapy, patient 
complaints of acute abdomen due to 
hemoperitoneum due to perforation of 
trophoblastic mass. Emergency laparotomy 
was performed, found hemoperitoneum and 
perforation on the upper left side of the uterus, 
total hysterectomy was performed.
Figure 1. Malignant mass invaded to myometrium
Figure 2. The specimen demonstrated perforation on the 
upper left side of the uterus   
plateau or persistence value of hCG, the presence 
of metastatic disease, or picture of invasive mass 
out of uterine cavity (such as myometrium) after 
molar evacuation could be used to diagnose 
GTN. On the other side histopathology results 
was used to classify GTN by its characteristics, for 
example: invasive mole have a risk of perforation, 
choriocarcinoma have a high risk of metastases, 
ETT or PSTT usually resistance to chemotherapy.
When GTN is suspected or established, a 
metastatic workup and an evaluation for risk 
factor should be performed. Along with complete 
history and physical examination, complete 
blood count, including coagulation studies, renal 
and liver function test and quantitative hCG 
level should be performed. Radiologic studies, 
such as pelvic ultrasound, chest x-ray, CT scan 
or brain MRI also recommended, if there was a 
sign of neurologic defi cits, to detect any site of 
metastases. 2,5
GTN metastases occur by hematogenous 
spread to the lungs (80%), vagina (30%), brain (10%) 
and liver (10%). Biopsies are not recommended 
because of the high risk of bleeding.2,5
What to do after diagnosing GTN? 2,5 
Treatment of GTN is based on risk groups 
classifi cation by stage and scoring system using 
FIGO or modifi ed WHO prognostic scoring and 
the pathology fi ndings. Only GTN that originated 
from previous molar pregnancy or low-risk 
GTN with single chemotherapy agent could be 
managed by general OBGYN; others should be 
managed by oncology-gynaecologist.
Prior to treatment, OBGYN should classify 
the disease to choose the right treatment plan. 
There were several classifi cations of GTN, such 
as Hammond, FIGO and WHO modifi ed FIGO 
classifi cation. Chemotherapy given did not 
correlate with the staging (FIGO), but depend on 
the Hammond classifi cation or WHO modifi ed 
FIGO classifi cation.
Hammond classifi es malignant GTN divided 
into good prognostic GTN and poor prognostic 
GTN; metastatic GTN is diagnosed when we 
found nodules on other organs, except vagina 
and lungs.
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Table 1. Metastatic GTN Classifi cation Based on Hammond (1981)
Table 2. GTN Staging by FIGO
Good 
Prognosis
Stage Description
Urinary hCG 
Serum hCG 
Symptom 
present 
Liver or brain 
metastases Prior 
chemotherapy
Following term 
pregnancy
I
II
III
IV
<105 IU/lt
<4x104 mIU/ml
< 4 months
No
No
No
Disease confi ned to the uterus
Disease extend outside uterus but is limited to 
genital structures (adnexa, vagina, broad ligament)
Disease extends to lungs with or without genital 
tract involvement
Disease involves other metastatic sites
>105 IU/lt
>4x104 mIU/ml
> 4 months
Yes
Yes
Yes
Poor 
Prognosis
The FIGO stage is followed by the Modifi ed 
WHO score and separated by a colon. Based on 
Hammond nonmetastatic classifi cation (FIGO: 
stage I) and low-risk metastatic (FIGO: stages II 
and III or score<7 due to WHO modifi ed FIGO 
classifi cation) GTN can be treated with single-
agent chemotherapy resulting in a survival rate 
approaching 100%.2,5
High-risk GTN (FIGO: stages II-IV, score≥7 due 
to WHO modifi ed FIGO classifi cation) requires 
initial multiagent chemotherapy with orwithout 
adjuvant radiation and surgery to achieve a 
survival rate of 80-90%.2,5
The overall cure rate was 90% with 
chemotherapy. However, for PSTT and ETT, 
Hysterectomy with lymph node dissection is 
the treatment of choice with survival rate is 
approximately 100% for nonmetastatic disease 
and 50-60% for metastatic disease.2,5
Table 3. Modifi ed WHO Prognostic Scoring System as Adapted by FIGO
Risk factor Score
0 1 2 4
Age, yo
Antecedent pregnancy
Pregnancy even to 
treatment interval, mo
Pretreatment hCG, 
mIU/ml
Largest tumour mass 
including uterus, cm
Site of metastases
No. of metastases
Previous failed 
chemotherapy
≤39
mole
<4
< 103
<3
-
-
-
>39
abortion
4-6
103-104
3-4
Spleen, 
kidney
1-4
-
-
term
7-12
104-105
≥5
GI tract
5-8
Single-
drug
-
>12
> 105
-
Brain, liver
>8
≥ 2 drug
How to treat low-risk GTN?
There were several different outpatient 
chemotherapy protocols have been used. Benefi ts 
seem to be greater when hCG concentration is 
below 1500 IU/L at the time of evacuation2, and 
the adverse side effect rate was much greater 
with combination therapy (62%) than with single-
agent methotrexate (29%) or actinomycin D 
(19%).5
The three most common regimens used are: 
weekly low-dose intramuscular (IM) MTX 0.4 mg/
kg (maximum 25mg/day) for 5 day, repeat every 
14 days; pulsed doses of ActD 1.25mg/m2repeat 
every two weeks; and several other dosing 
regimens of MTX 1mg/kg IM (d 1,3,5,7) with or 
without folinic acid (FA) rescue 0.1 mg/kg IM 
(d 2,4,6,8) repeat every 15-18 days. The survival 
rate using this kind of regiments was more than 
90%.2,5
Mortality rates associated with IM reached 
15%. In the presence of metastases, CCA had a 
mortality rate of 100%, and about 60% when the 
hysterectomy was performed to treat apparent 
nonmetastatic disease.2
What to do next?
Defi nitive follow up requires serial quantitative 
hCG measurements every 1-2 weeks until 
achieving the normal level, and it is consolidation 
dose by continuing the follow up with three 
consecutive tests that show normal level (depend 
on the normal laboratory value) after treatment. 
After that, hCG levels should be determined every 
1-month intervals for 12 months. The relapse risk 
was about 3% in the fi rst year after completing 
the therapy.3,7-8
Follow up
Contraception (preferably using oral 
contraceptives) should be maintained during 
treatment and for one year after completion 
of chemotherapy.1-3,9 Because there is 1-2% risk 
of second gestational trophoblastic disease in 
subsequent pregnancies, pelvic ultrasound is 
recommended in the fi rst trimester to confi rm a 
normal gestation. The products of conception or 
placentas should be examined by histopathology 
and serum quantitative hCG level should be 
determined six weeks after any pregnancy.3
Most woman resumes normal ovarian function 
after chemotherapy and exhibits no increase in 
infertility.  No evidence for reactivation of the 
disease because of subsequent pregnancy.3,10. 
Primary remission was achieved in 48-67% of 
patients with the fi rst single-agent chemotherapy 
regimen. From 1-14% of patients needed 
multiagent chemotherapy after failed sequential 
single-agent chemotherapy with or without 
surgery to achieve remission, but eventually, all 
patients were cured.3
The most common reasons for unsuccessful 
GTN treatment are  use of single-agent 
chemotherapy for patients with high-risk disease; 
inappropriate use of weekly IM methotrexate 
chemotherapy for treatment of patients with 
metastatic disease, FIGO scores ≥ 7, and/or 
nonpostmolar choriocarcinoma.3
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CONCLUSION 
Inadequate treatment due to inadequate staging 
is the most common reason for unsuccessful GTN 
treatment, and increase patient morbidity. It is 
important to know how to perform GTN staging 
using the WHO modifi ed staging score, adapted 
by FIGO and how to perform adequate treatment 
for this disease. Histopathology also plays an 
essential role to decide the mode of treatment that 
should be given since PSTT, and ETT treatment of 
choice is not using chemotherapy.
Since there is a risk of repeated gestational 
trophoblastic disease, it is important to use 
contraception during treatment and one year 
after completion of chemotherapy. It is also 
recommended to examine the conception 
product or placenta by histopathology and serum 
quantitative hCG level should be determined six 
weeks after any pregnancy.
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